Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

NCT ID: NCT02402933

Last Updated: 2019-09-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-03-31
• Study Completion Date: 2015-08-31

Brief Summary

Up to fifty (50) children and adolescents with type 1 diabetes (T1D) aged 4 to ˂18 years at time of enrolment will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of Nasal Glucagon (LY900018) in treating episodes of hypoglycemia.

Detailed Description

This study is designed to evaluate the effectiveness of nasal glucagon (NG) administered under clinical use conditions in treating episodes of moderate or severe hypoglycemia in persons with T1D.

This study also aims to assess the ease with which caregivers can administer the experimental medication in treatment of hypoglycemic events.

Conditions

Hypoglycemia; Diabetes Mellitus

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Nasal Glucagon

A single dose of 3mg glucagon nasal powder administered using a nasal powder delivery device for the treatment of moderate or severe hypoglycemic events; a maximum of 4 events per participant during the study.

Group Type: EXPERIMENTAL

Nasal Glucagon

Intervention Type: DRUG

3 mg nasal glucagon powder

Interventions

Nasal Glucagon

3 mg nasal glucagon powder

Intervention Type: DRUG

Other Intervention Names

Dry-Mist nasal glucagon; AMG504-1; LY900018

Eligibility Criteria

Inclusion Criteria

• Availability for the entire study period.
• Motivated Child/Adolescent with diabetes (C/AWD) and caregiver(s) and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the qualified investigator or designee.
• C/AWD lives with one or more caregivers who are available to administer the glucagon in case of an episode of severe or moderate hypoglycemia.
• Male or female C/AWD with a history of type 1 diabetes >1 year.
• C/AWD aged of at least 4 years of age but less than 18 years.
• A female C/AWD must meet one of the following criteria:

a) Participant is of child-bearing potential and agrees to use one of the accepted contraceptive regimens throughout the entire duration of the study (from the pre-trial evaluation and enrollment visit until study completion). An acceptable method of contraception includes one of the following: (i) Abstinence from heterosexual intercourse (ii) Systemic contraceptives (birth control pills, injectable/implantable/ insertable hormonal birth control products, transdermal patch) (iii) Intrauterine device (iv) Condom with spermicide, OR b) Participant is of non-child-bearing potential, defined as a female who had had a hysterectomy or tubal ligation, is clinically considered infertile or has not yet reached menarche.

• In good general health with no conditions that could influence the outcome of the trial, and in the judgment of the Investigator is a suitable candidate for the study based on review of available medical history, physical examination and clinical laboratory evaluations.
• Willingness to adhere to the protocol requirements.

Exclusion Criteria

• Females who are pregnant according to a positive urine pregnancy test, actively attempting to get pregnant, or lactating.
• History of significant hypersensitivity to glucagon, or any related products as well as severe hypersensitivity reactions (such as angioedema) to any drugs.
• Presence of cardiovascular, gastrointestinal, liver or kidney disease, or any other conditions which in the judgment of the investigator could interfere with the absorption, distribution, metabolism or excretion of drugs or could potentiate or predispose to undesired effects.
• Presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma.
• Use of daily systemic beta-blockers, indomethacin, warfarin or anticholinergic drugs.
• Concomitant maintenance therapy with any drug that would influence the outcome of the trial, at the discretion of the Investigator and the Sponsor.
• Regular consumption of 3 or more units of alcoholic beverages per day.
• Current participation in another clinical trial, intent to enroll in another clinical trial during this clinical study or use of an Investigational Product (in another clinical trial) within the prior 30 days.

• Minimum Eligible Age: 4 Years
• Maximum Eligible Age: 17 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eli Lilly and Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Private Clinic

Tallahassee, Florida, United States

Private Clinic

Baltimore, Maryland, United States

New England Diabetes and Endocrinology Center (NEDEC)

Waltham, Massachusetts, United States

Countries

United States

Other Identifiers

I8R-MC-B001

Identifier Type: OTHER

Identifier Source: secondary_id

AMG109

Identifier Type: OTHER

Identifier Source: secondary_id

16423

Identifier Type: -

Identifier Source: org_study_id